Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.
Identifieur interne : 001042 ( Ncbi/Curation ); précédent : 001041; suivant : 001043Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.
Auteurs : Marina De Tommaso [Italie] ; Nicola Specchio ; Vittorio Sciruicchio ; Olimpia Difruscolo ; Luigi Maria SpecchioSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2004.
English descriptors
- KwdEn :
- Adult, Aged, Cognition Disorders (diagnosis), Cognition Disorders (epidemiology), Cognition Disorders (etiology), Demography, Female, Humans, Huntington Disease (complications), Huntington Disease (drug therapy), Huntington Disease (genetics), Male, Middle Aged, Movement Disorders (diagnosis), Movement Disorders (epidemiology), Movement Disorders (etiology), Neuroprotective Agents (therapeutic use), Phenylcarbamates (therapeutic use), Prospective Studies, Severity of Illness Index, Trinucleotide Repeat Expansion (genetics).
- MESH :
- chemical , therapeutic use : Neuroprotective Agents, Phenylcarbamates.
- complications : Huntington Disease.
- diagnosis : Cognition Disorders, Movement Disorders.
- drug therapy : Huntington Disease.
- epidemiology : Cognition Disorders, Movement Disorders.
- etiology : Cognition Disorders, Movement Disorders.
- genetics : Huntington Disease, Trinucleotide Repeat Expansion.
- Adult, Aged, Demography, Female, Humans, Male, Middle Aged, Prospective Studies, Severity of Illness Index.
Abstract
To evaluate the efficacy of rivastigmine on motor and cognitive impairment in Huntington's disease (HD), we carried out a prospective, open-label, randomized, controlled study. Twenty-one HD patients were enrolled: 14 were randomly sorted into medication and 7 to no-treatment groups. Clinical and demographic features were similar between groups. After 8 months, an efficacy evaluation was carried out to compare the two groups. The improvement of cholinergic transmission in HD patients seemed to have a slight effect in ameliorating cognitive performance and slowing motor deterioration.
DOI: 10.1002/mds.20235
PubMed: 15390067
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003246
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003246
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003474
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001042
Links to Exploration step
pubmed:15390067Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.</title><author><name sortKey="De Tommaso, Marina" sort="De Tommaso, Marina" uniqKey="De Tommaso M" first="Marina" last="De Tommaso">Marina De Tommaso</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy. m.detommaso@neurol.uniba.it</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological and Psychiatric Sciences, University of Bari, Bari</wicri:regionArea><wicri:noRegion>Bari</wicri:noRegion></affiliation></author><author><name sortKey="Specchio, Nicola" sort="Specchio, Nicola" uniqKey="Specchio N" first="Nicola" last="Specchio">Nicola Specchio</name></author><author><name sortKey="Sciruicchio, Vittorio" sort="Sciruicchio, Vittorio" uniqKey="Sciruicchio V" first="Vittorio" last="Sciruicchio">Vittorio Sciruicchio</name></author><author><name sortKey="Difruscolo, Olimpia" sort="Difruscolo, Olimpia" uniqKey="Difruscolo O" first="Olimpia" last="Difruscolo">Olimpia Difruscolo</name></author><author><name sortKey="Specchio, Luigi Maria" sort="Specchio, Luigi Maria" uniqKey="Specchio L" first="Luigi Maria" last="Specchio">Luigi Maria Specchio</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15390067</idno><idno type="pmid">15390067</idno><idno type="doi">10.1002/mds.20235</idno><idno type="wicri:Area/PubMed/Corpus">003246</idno><idno type="wicri:Area/PubMed/Curation">003246</idno><idno type="wicri:Area/PubMed/Checkpoint">003474</idno><idno type="wicri:Area/Ncbi/Merge">001042</idno><idno type="wicri:Area/Ncbi/Curation">001042</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.</title><author><name sortKey="De Tommaso, Marina" sort="De Tommaso, Marina" uniqKey="De Tommaso M" first="Marina" last="De Tommaso">Marina De Tommaso</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy. m.detommaso@neurol.uniba.it</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological and Psychiatric Sciences, University of Bari, Bari</wicri:regionArea><wicri:noRegion>Bari</wicri:noRegion></affiliation></author><author><name sortKey="Specchio, Nicola" sort="Specchio, Nicola" uniqKey="Specchio N" first="Nicola" last="Specchio">Nicola Specchio</name></author><author><name sortKey="Sciruicchio, Vittorio" sort="Sciruicchio, Vittorio" uniqKey="Sciruicchio V" first="Vittorio" last="Sciruicchio">Vittorio Sciruicchio</name></author><author><name sortKey="Difruscolo, Olimpia" sort="Difruscolo, Olimpia" uniqKey="Difruscolo O" first="Olimpia" last="Difruscolo">Olimpia Difruscolo</name></author><author><name sortKey="Specchio, Luigi Maria" sort="Specchio, Luigi Maria" uniqKey="Specchio L" first="Luigi Maria" last="Specchio">Luigi Maria Specchio</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Cognition Disorders (diagnosis)</term><term>Cognition Disorders (epidemiology)</term><term>Cognition Disorders (etiology)</term><term>Demography</term><term>Female</term><term>Humans</term><term>Huntington Disease (complications)</term><term>Huntington Disease (drug therapy)</term><term>Huntington Disease (genetics)</term><term>Male</term><term>Middle Aged</term><term>Movement Disorders (diagnosis)</term><term>Movement Disorders (epidemiology)</term><term>Movement Disorders (etiology)</term><term>Neuroprotective Agents (therapeutic use)</term><term>Phenylcarbamates (therapeutic use)</term><term>Prospective Studies</term><term>Severity of Illness Index</term><term>Trinucleotide Repeat Expansion (genetics)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term><term>Phenylcarbamates</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Huntington Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cognition Disorders</term><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Huntington Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cognition Disorders</term><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cognition Disorders</term><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Huntington Disease</term><term>Trinucleotide Repeat Expansion</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Demography</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To evaluate the efficacy of rivastigmine on motor and cognitive impairment in Huntington's disease (HD), we carried out a prospective, open-label, randomized, controlled study. Twenty-one HD patients were enrolled: 14 were randomly sorted into medication and 7 to no-treatment groups. Clinical and demographic features were similar between groups. After 8 months, an efficacy evaluation was carried out to compare the two groups. The improvement of cholinergic transmission in HD patients seemed to have a slight effect in ameliorating cognitive performance and slowing motor deterioration.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001042 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001042 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:15390067
|texte= Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:15390067" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |